Physician profile
Mario Werbin
NPI 1861407686
$11,048.21
in general payments reported to CMS, 2019-2025
35 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,826 · 2020: $1,404 · 2021: $2,050 · 2022: $1,268 · 2023: $1,432 · 2024: $1,015 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,498.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,644.63 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $1,296.14 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $922.82 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $836.34 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $774.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $726.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $710.48 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Teva Pharmaceuticals USA, INC. | $621.00 | 2019-2022 | |
| Amarin Pharma, INC. | $594.40 | 2019-2022 | |
| Amgen INC. | $320.56 | 2019-2024 | Repatha, Otezla, Prolia |
| Exact Sciences Corporation | $270.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $269.83 | 2021 | |
| Sanofi-Aventis U.S. LLC | $250.69 | 2019 | |
| Merck Sharp & Dohme LLC | $220.92 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.13 | 2019-2023 | Relistor |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $187.46 | 2019-2020 | |
| Angiodynamics, INC. | $159.61 | 2023 | Nanoknife |
| Esperion Therapeutics, INC. | $140.17 | 2021 | |
| Ironwood Pharmaceuticals, INC | $125.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $119.23 | 2024 | Quviviq |
| Heartflow, INC. | $119.06 | 2023 | Ffrct |
| Kowa Pharmaceuticals America, INC. | $75.59 | 2019-2021 | |
| Astellas Pharma US INC | $57.56 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $57.41 | 2019-2022 | |
| Boston Scientific Corporation | $55.25 | 2025 | General - Pain Management |
| Almatica Pharma LLC | $52.74 | 2022 | |
| Mylan Specialty L.P. | $45.64 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $34.60 | 2021 | |
| Lundbeck LLC | $30.81 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $26.43 | 2019 | |
| Vanda Pharmaceuticals INC. | $25.60 | 2022 | |
| Abbvie INC. | $21.40 | 2022 | |
| Abbott Laboratories | $18.67 | 2023 | Proclaim |
| Sanofi Pasteur INC. | $17.38 | 2020 | |
| Therapeuticsmd, INC. | $16.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Werbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.